央行強調應全面放開和鼓勵生育 生育健康領域產業化有望獲突破
央行官網昨日發佈工作論文《關於我國人口轉型的認識和應對之策》。

論文指出:“我國要認清人口形勢已經改變,要認識到人口紅利當時用得舒服,事後是需要償還的負債;要認識到人口慣性是跨代際的巨大力量,其反作用力將導致人口反方向變化;要認識到教育和科技進步難以彌補人口的下降。為此,應全面放開和鼓勵生育,切實解決婦女在懷孕、生產、入托、入學中的困難,綜合施策,久久為功,努力實現2035年遠景規劃和百年奮鬥目標。”嚴厲的口吻透露出我國人口轉型已迫在眉睫。
隨着全面放開和鼓勵生育,我國生育健康領域產業化必然實現進一步的突破與發展。今日港A兩地涉及生育的概念股均有明顯表現。據悉,在港股上市的貝康醫療(2170.HK)作為中國輔助生殖基因測序產業第一股,致力於高通量測序在輔助生殖領域的臨牀研究和應用。開發全生育週期產品圍繞三級預防措施體系,實現輔助生殖領域的精準醫療。貝康醫療也是第一家研製PGT-A標準品的研製單位,第一家參與發佈《胚胎植入前染色體非整倍體檢測試劑的質量控制技術評價指南》的公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.